BTK and lymphoma: Unregulated BCR signaling, on the other hand, contributes to the development and persistence of B cell-derived cancers (6, 7), as evidenced by the effectiveness of inhibitors targeting the proximal signaling proteins Bruton tyrosine kinase (BTK) and PI3K in B-cell leukemias and lymphomas (8).